Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
Journal Title: World Journal of Clinical Oncology - Year 2013, Vol 4, Issue 2
Abstract
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death in both men and women in the United States. Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease. Improvements in overall survival and quality of life have been modest. Improved knowledge of the aberrant molecular signaling pathways found in NSCLC has led to the development of biomarkers with associated targeted therapeutics, thus changing the treatment paradigm for many NSCLC patients. In this review, we present a summary of many of the currently investigated biologic targets in NSCLC, discuss their current clinical trial status, and also discuss the potential for development of other targeted agents.
Authors and Affiliations
Soley Bayraktar, Caio M Rocha-Lima
Keywords
Related Articles
- EP ID EP679596
- DOI 10.5306/wjco.v4.i2.29
- Views 41
- Downloads 0
Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas
Data regarding patients with a histologically confirmed diagnosis of locally advanced NPC (T2bN0M0-T4bN3M0) and treated with chemotherapy and radiotherapy from March 2006 to March 2012 at the participating Institutions,...
Non-AIDS-related Kaposi's sarcoma: A single-institution experience
Disease control rate is 93.7%.
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death in both men and women in the United States. Platinum-based doublet chemotherapy has been a standard for patients with advanced stage di...
Statin a day keeps cancer at bay
In addition to cholesterol reduction, statins, currently the most commonly prescribed drug in the world, have been shown to have anti-neoplastic and immunomodulatory effects. Several observational studies and meta-analys...